Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Broluzumab Biosimilars Market Research Report 2025

Global Broluzumab Biosimilars Market Research Report 2025

Industry: Pharma & Healthcare

Published Date: 2025-01-16

Pages: 119 Pages

Report ld: 3456255

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global market for Broluzumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

biaoTi REPORT SCOPE

This report aims to provide a comprehensive presentation of the global market for Broluzumab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Broluzumab Biosimilars.

The Broluzumab Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Broluzumab Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Broluzumab Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

By Company

Novartis

Genentech

Roche

Pfizer

Sartorius

Eli Lilly

Bayer

Amgen

PlantForm

PharmaPraxis

Samsung Bioepis

Centus

Cadila Pharmaceuticals

Dr Reddy's

Aurobindo Pharma

Biocad

MAbxience

Hetero

Biocon

Kirin Biologics

Mylan

BeiGene

Innovent

Qilu Pharmaceutical

Hengrui Pharmaceuticals

Hisun Pharmaceutical

TOT BIOPHARM

Luye Pharmaceutical

Henlius

Segment by Type

Beovu

Vsiqq

Others

Segment by Application

ARMD

Kaposi Sarcoma

Glioblastoma

Consumption by Region

North America

U.S.

Canada

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Europe

Germany

France

U.K.

Italy

Russia

Latin America

Mexico

Brazil

Argentina

Middle East and Africa

Turkey

Saudi Arabia

U.A.E

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Detailed analysis of Broluzumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Sales, revenue of Broluzumab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 9: The main points and conclusions of the report.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Broluzumab Biosimilars Market Overview

1.1 Product Definition

1.2 Broluzumab Biosimilars by Type

1.2.1 Global Broluzumab Biosimilars Market Value Comparison by Type (2024 VS 2031)

1.2.2 Beovu

1.2.3 Vsiqq

1.2.4 Others

1.3 Broluzumab Biosimilars by Application

1.3.1 Global Broluzumab Biosimilars Market Value by Application (2024 VS 2031)

1.3.2 ARMD

1.3.3 Kaposi Sarcoma

1.3.4 Glioblastoma

1.4 Global Broluzumab Biosimilars Market Size Estimates and Forecasts

1.4.1 Global Broluzumab Biosimilars Revenue 2020-2031

1.4.2 Global Broluzumab Biosimilars Sales 2020-2031

1.4.3 Global Broluzumab Biosimilars Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Broluzumab Biosimilars Market Competition by Manufacturers

2.1 Global Broluzumab Biosimilars Sales Market Share by Manufacturers (2020-2025)

2.2 Global Broluzumab Biosimilars Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Broluzumab Biosimilars Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Broluzumab Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Broluzumab Biosimilars, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Broluzumab Biosimilars, Product Type & Application

2.7 Global Key Manufacturers of Broluzumab Biosimilars, Date of Enter into This Industry

2.8 Global Broluzumab Biosimilars Market Competitive Situation and Trends

2.8.1 Global Broluzumab Biosimilars Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Broluzumab Biosimilars Players Market Share by Revenue

2.8.3 Global Broluzumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Broluzumab Biosimilars Market Scenario by Region

3.1 Global Broluzumab Biosimilars Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Broluzumab Biosimilars Sales by Region: 2020-2031

3.2.1 Global Broluzumab Biosimilars Sales by Region: 2020-2025

3.2.2 Global Broluzumab Biosimilars Sales by Region: 2026-2031

3.3 Global Broluzumab Biosimilars Revenue by Region: 2020-2031

3.3.1 Global Broluzumab Biosimilars Revenue by Region: 2020-2025

3.3.2 Global Broluzumab Biosimilars Revenue by Region: 2026-2031

3.4 North America Broluzumab Biosimilars Market Facts & Figures by Country

3.4.1 North America Broluzumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Broluzumab Biosimilars Sales by Country (2020-2031)

3.4.3 North America Broluzumab Biosimilars Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Broluzumab Biosimilars Market Facts & Figures by Country

3.5.1 Europe Broluzumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Broluzumab Biosimilars Sales by Country (2020-2031)

3.5.3 Europe Broluzumab Biosimilars Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Broluzumab Biosimilars Market Facts & Figures by Region

3.6.1 Asia Pacific Broluzumab Biosimilars Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Broluzumab Biosimilars Sales by Region (2020-2031)

3.6.3 Asia Pacific Broluzumab Biosimilars Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Broluzumab Biosimilars Market Facts & Figures by Country

3.7.1 Latin America Broluzumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Broluzumab Biosimilars Sales by Country (2020-2031)

3.7.3 Latin America Broluzumab Biosimilars Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Broluzumab Biosimilars Market Facts & Figures by Country

3.8.1 Middle East and Africa Broluzumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Broluzumab Biosimilars Sales by Country (2020-2031)

3.8.3 Middle East and Africa Broluzumab Biosimilars Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Broluzumab Biosimilars Sales by Type (2020-2031)

4.1.1 Global Broluzumab Biosimilars Sales by Type (2020-2025)

4.1.2 Global Broluzumab Biosimilars Sales by Type (2026-2031)

4.1.3 Global Broluzumab Biosimilars Sales Market Share by Type (2020-2031)

4.2 Global Broluzumab Biosimilars Revenue by Type (2020-2031)

4.2.1 Global Broluzumab Biosimilars Revenue by Type (2020-2025)

4.2.2 Global Broluzumab Biosimilars Revenue by Type (2026-2031)

4.2.3 Global Broluzumab Biosimilars Revenue Market Share by Type (2020-2031)

4.3 Global Broluzumab Biosimilars Price by Type (2020-2031)

5 Segment by Application

5.1 Global Broluzumab Biosimilars Sales by Application (2020-2031)

5.1.1 Global Broluzumab Biosimilars Sales by Application (2020-2025)

5.1.2 Global Broluzumab Biosimilars Sales by Application (2026-2031)

5.1.3 Global Broluzumab Biosimilars Sales Market Share by Application (2020-2031)

5.2 Global Broluzumab Biosimilars Revenue by Application (2020-2031)

5.2.1 Global Broluzumab Biosimilars Revenue by Application (2020-2025)

5.2.2 Global Broluzumab Biosimilars Revenue by Application (2026-2031)

5.2.3 Global Broluzumab Biosimilars Revenue Market Share by Application (2020-2031)

5.3 Global Broluzumab Biosimilars Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Novartis

6.1.1 Novartis Company Information

6.1.2 Novartis Description and Business Overview

6.1.3 Novartis Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Novartis Broluzumab Biosimilars Product Portfolio

6.1.5 Novartis Recent Developments/Updates

6.2 Genentech

6.2.1 Genentech Company Information

6.2.2 Genentech Description and Business Overview

6.2.3 Genentech Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Genentech Broluzumab Biosimilars Product Portfolio

6.2.5 Genentech Recent Developments/Updates

6.3 Roche

6.3.1 Roche Company Information

6.3.2 Roche Description and Business Overview

6.3.3 Roche Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Roche Broluzumab Biosimilars Product Portfolio

6.3.5 Roche Recent Developments/Updates

6.4 Pfizer

6.4.1 Pfizer Company Information

6.4.2 Pfizer Description and Business Overview

6.4.3 Pfizer Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Pfizer Broluzumab Biosimilars Product Portfolio

6.4.5 Pfizer Recent Developments/Updates

6.5 Sartorius

6.5.1 Sartorius Company Information

6.5.2 Sartorius Description and Business Overview

6.5.3 Sartorius Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Sartorius Broluzumab Biosimilars Product Portfolio

6.5.5 Sartorius Recent Developments/Updates

6.6 Eli Lilly

6.6.1 Eli Lilly Company Information

6.6.2 Eli Lilly Description and Business Overview

6.6.3 Eli Lilly Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Eli Lilly Broluzumab Biosimilars Product Portfolio

6.6.5 Eli Lilly Recent Developments/Updates

6.7 Bayer

6.7.1 Bayer Company Information

6.7.2 Bayer Description and Business Overview

6.7.3 Bayer Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Bayer Broluzumab Biosimilars Product Portfolio

6.7.5 Bayer Recent Developments/Updates

6.8 Amgen

6.8.1 Amgen Company Information

6.8.2 Amgen Description and Business Overview

6.8.3 Amgen Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Amgen Broluzumab Biosimilars Product Portfolio

6.8.5 Amgen Recent Developments/Updates

6.9 PlantForm

6.9.1 PlantForm Company Information

6.9.2 PlantForm Description and Business Overview

6.9.3 PlantForm Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.9.4 PlantForm Broluzumab Biosimilars Product Portfolio

6.9.5 PlantForm Recent Developments/Updates

6.10 PharmaPraxis

6.10.1 PharmaPraxis Company Information

6.10.2 PharmaPraxis Description and Business Overview

6.10.3 PharmaPraxis Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.10.4 PharmaPraxis Broluzumab Biosimilars Product Portfolio

6.10.5 PharmaPraxis Recent Developments/Updates

6.11 Samsung Bioepis

6.11.1 Samsung Bioepis Company Information

6.11.2 Samsung Bioepis Description and Business Overview

6.11.3 Samsung Bioepis Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Samsung Bioepis Broluzumab Biosimilars Product Portfolio

6.11.5 Samsung Bioepis Recent Developments/Updates

6.12 Centus

6.12.1 Centus Company Information

6.12.2 Centus Description and Business Overview

6.12.3 Centus Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Centus Broluzumab Biosimilars Product Portfolio

6.12.5 Centus Recent Developments/Updates

6.13 Cadila Pharmaceuticals

6.13.1 Cadila Pharmaceuticals Company Information

6.13.2 Cadila Pharmaceuticals Description and Business Overview

6.13.3 Cadila Pharmaceuticals Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Cadila Pharmaceuticals Broluzumab Biosimilars Product Portfolio

6.13.5 Cadila Pharmaceuticals Recent Developments/Updates

6.14 Dr Reddy's

6.14.1 Dr Reddy's Company Information

6.14.2 Dr Reddy's Description and Business Overview

6.14.3 Dr Reddy's Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.14.4 Dr Reddy's Broluzumab Biosimilars Product Portfolio

6.14.5 Dr Reddy's Recent Developments/Updates

6.15 Aurobindo Pharma

6.15.1 Aurobindo Pharma Company Information

6.15.2 Aurobindo Pharma Description and Business Overview

6.15.3 Aurobindo Pharma Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.15.4 Aurobindo Pharma Broluzumab Biosimilars Product Portfolio

6.15.5 Aurobindo Pharma Recent Developments/Updates

6.16 Biocad

6.16.1 Biocad Company Information

6.16.2 Biocad Description and Business Overview

6.16.3 Biocad Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.16.4 Biocad Broluzumab Biosimilars Product Portfolio

6.16.5 Biocad Recent Developments/Updates

6.17 MAbxience

6.17.1 MAbxience Company Information

6.17.2 MAbxience Description and Business Overview

6.17.3 MAbxience Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.17.4 MAbxience Broluzumab Biosimilars Product Portfolio

6.17.5 MAbxience Recent Developments/Updates

6.18 Hetero

6.18.1 Hetero Company Information

6.18.2 Hetero Description and Business Overview

6.18.3 Hetero Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.18.4 Hetero Broluzumab Biosimilars Product Portfolio

6.18.5 Hetero Recent Developments/Updates

6.19 Biocon

6.19.1 Biocon Company Information

6.19.2 Biocon Description and Business Overview

6.19.3 Biocon Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.19.4 Biocon Broluzumab Biosimilars Product Portfolio

6.19.5 Biocon Recent Developments/Updates

6.20 Kirin Biologics

6.20.1 Kirin Biologics Company Information

6.20.2 Kirin Biologics Description and Business Overview

6.20.3 Kirin Biologics Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.20.4 Kirin Biologics Broluzumab Biosimilars Product Portfolio

6.20.5 Kirin Biologics Recent Developments/Updates

6.21 Mylan

6.21.1 Mylan Company Information

6.21.2 Mylan Description and Business Overview

6.21.3 Mylan Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.21.4 Mylan Broluzumab Biosimilars Product Portfolio

6.21.5 Mylan Recent Developments/Updates

6.22 BeiGene

6.22.1 BeiGene Company Information

6.22.2 BeiGene Description and Business Overview

6.22.3 BeiGene Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.22.4 BeiGene Broluzumab Biosimilars Product Portfolio

6.22.5 BeiGene Recent Developments/Updates

6.23 Innovent

6.23.1 Innovent Company Information

6.23.2 Innovent Description and Business Overview

6.23.3 Innovent Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.23.4 Innovent Broluzumab Biosimilars Product Portfolio

6.23.5 Innovent Recent Developments/Updates

6.24 Qilu Pharmaceutical

6.24.1 Qilu Pharmaceutical Company Information

6.24.2 Qilu Pharmaceutical Description and Business Overview

6.24.3 Qilu Pharmaceutical Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.24.4 Qilu Pharmaceutical Broluzumab Biosimilars Product Portfolio

6.24.5 Qilu Pharmaceutical Recent Developments/Updates

6.25 Hengrui Pharmaceuticals

6.25.1 Hengrui Pharmaceuticals Company Information

6.25.2 Hengrui Pharmaceuticals Description and Business Overview

6.25.3 Hengrui Pharmaceuticals Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.25.4 Hengrui Pharmaceuticals Broluzumab Biosimilars Product Portfolio

6.25.5 Hengrui Pharmaceuticals Recent Developments/Updates

6.26 Hisun Pharmaceutical

6.26.1 Hisun Pharmaceutical Company Information

6.26.2 Hisun Pharmaceutical Description and Business Overview

6.26.3 Hisun Pharmaceutical Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.26.4 Hisun Pharmaceutical Broluzumab Biosimilars Product Portfolio

6.26.5 Hisun Pharmaceutical Recent Developments/Updates

6.27 TOT BIOPHARM

6.27.1 TOT BIOPHARM Company Information

6.27.2 TOT BIOPHARM Description and Business Overview

6.27.3 TOT BIOPHARM Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.27.4 TOT BIOPHARM Broluzumab Biosimilars Product Portfolio

6.27.5 TOT BIOPHARM Recent Developments/Updates

6.28 Luye Pharmaceutical

6.28.1 Luye Pharmaceutical Company Information

6.28.2 Luye Pharmaceutical Description and Business Overview

6.28.3 Luye Pharmaceutical Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.28.4 Luye Pharmaceutical Broluzumab Biosimilars Product Portfolio

6.28.5 Luye Pharmaceutical Recent Developments/Updates

6.29 Henlius

6.29.1 Henlius Company Information

6.29.2 Henlius Description and Business Overview

6.29.3 Henlius Broluzumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.29.4 Henlius Broluzumab Biosimilars Product Portfolio

6.29.5 Henlius Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Broluzumab Biosimilars Industry Chain Analysis

7.2 Broluzumab Biosimilars Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Broluzumab Biosimilars Production Mode & Process Analysis

7.4 Broluzumab Biosimilars Sales and Marketing

7.4.1 Broluzumab Biosimilars Sales Channels

7.4.2 Broluzumab Biosimilars Distributors

7.5 Broluzumab Biosimilars Customer Analysis

8 Broluzumab Biosimilars Market Dynamics

8.1 Broluzumab Biosimilars Industry Trends

8.2 Broluzumab Biosimilars Market Drivers

8.3 Broluzumab Biosimilars Market Challenges

8.4 Broluzumab Biosimilars Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Broluzumab Biosimilars Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Broluzumab Biosimilars Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Broluzumab Biosimilars Market Competitive Situation by Manufacturers in 2024

Table 4. Global Broluzumab Biosimilars Sales (Units) of Key Manufacturers (2020-2025)

Table 5. Global Broluzumab Biosimilars Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Broluzumab Biosimilars Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Broluzumab Biosimilars Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Broluzumab Biosimilars Average Price (K USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Broluzumab Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Broluzumab Biosimilars, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Broluzumab Biosimilars, Product Type & Application

Table 12. Global Key Manufacturers of Broluzumab Biosimilars, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Broluzumab Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Broluzumab Biosimilars as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Broluzumab Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Broluzumab Biosimilars Sales by Region (2020-2025) & (Units)

Table 18. Global Broluzumab Biosimilars Sales Market Share by Region (2020-2025)

Table 19. Global Broluzumab Biosimilars Sales by Region (2026-2031) & (Units)

Table 20. Global Broluzumab Biosimilars Sales Market Share by Region (2026-2031)

Table 21. Global Broluzumab Biosimilars Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Broluzumab Biosimilars Revenue Market Share by Region (2020-2025)

Table 23. Global Broluzumab Biosimilars Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Broluzumab Biosimilars Revenue Market Share by Region (2026-2031)

Table 25. North America Broluzumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Broluzumab Biosimilars Sales by Country (2020-2025) & (Units)

Table 27. North America Broluzumab Biosimilars Sales by Country (2026-2031) & (Units)

Table 28. North America Broluzumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Broluzumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Broluzumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Broluzumab Biosimilars Sales by Country (2020-2025) & (Units)

Table 32. Europe Broluzumab Biosimilars Sales by Country (2026-2031) & (Units)

Table 33. Europe Broluzumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Broluzumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Broluzumab Biosimilars Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Broluzumab Biosimilars Sales by Region (2020-2025) & (Units)

Table 37. Asia Pacific Broluzumab Biosimilars Sales by Region (2026-2031) & (Units)

Table 38. Asia Pacific Broluzumab Biosimilars Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Broluzumab Biosimilars Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Broluzumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Broluzumab Biosimilars Sales by Country (2020-2025) & (Units)

Table 42. Latin America Broluzumab Biosimilars Sales by Country (2026-2031) & (Units)

Table 43. Latin America Broluzumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Broluzumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Broluzumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Broluzumab Biosimilars Sales by Country (2020-2025) & (Units)

Table 47. Middle East and Africa Broluzumab Biosimilars Sales by Country (2026-2031) & (Units)

Table 48. Middle East and Africa Broluzumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Broluzumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Broluzumab Biosimilars Sales (Units) by Type (2020-2025)

Table 51. Global Broluzumab Biosimilars Sales (Units) by Type (2026-2031)

Table 52. Global Broluzumab Biosimilars Sales Market Share by Type (2020-2025)

Table 53. Global Broluzumab Biosimilars Sales Market Share by Type (2026-2031)

Table 54. Global Broluzumab Biosimilars Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Broluzumab Biosimilars Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Broluzumab Biosimilars Revenue Market Share by Type (2020-2025)

Table 57. Global Broluzumab Biosimilars Revenue Market Share by Type (2026-2031)

Table 58. Global Broluzumab Biosimilars Price (K USD/Unit) by Type (2020-2025)

Table 59. Global Broluzumab Biosimilars Price (K USD/Unit) by Type (2026-2031)

Table 60. Global Broluzumab Biosimilars Sales (Units) by Application (2020-2025)

Table 61. Global Broluzumab Biosimilars Sales (Units) by Application (2026-2031)

Table 62. Global Broluzumab Biosimilars Sales Market Share by Application (2020-2025)

Table 63. Global Broluzumab Biosimilars Sales Market Share by Application (2026-2031)

Table 64. Global Broluzumab Biosimilars Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Broluzumab Biosimilars Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Broluzumab Biosimilars Revenue Market Share by Application (2020-2025)

Table 67. Global Broluzumab Biosimilars Revenue Market Share by Application (2026-2031)

Table 68. Global Broluzumab Biosimilars Price (K USD/Unit) by Application (2020-2025)

Table 69. Global Broluzumab Biosimilars Price (K USD/Unit) by Application (2026-2031)

Table 70. Novartis Company Information

Table 71. Novartis Description and Business Overview

Table 72. Novartis Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 73. Novartis Broluzumab Biosimilars Product

Table 74. Novartis Recent Developments/Updates

Table 75. Genentech Company Information

Table 76. Genentech Description and Business Overview

Table 77. Genentech Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 78. Genentech Broluzumab Biosimilars Product

Table 79. Genentech Recent Developments/Updates

Table 80. Roche Company Information

Table 81. Roche Description and Business Overview

Table 82. Roche Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 83. Roche Broluzumab Biosimilars Product

Table 84. Roche Recent Developments/Updates

Table 85. Pfizer Company Information

Table 86. Pfizer Description and Business Overview

Table 87. Pfizer Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 88. Pfizer Broluzumab Biosimilars Product

Table 89. Pfizer Recent Developments/Updates

Table 90. Sartorius Company Information

Table 91. Sartorius Description and Business Overview

Table 92. Sartorius Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 93. Sartorius Broluzumab Biosimilars Product

Table 94. Sartorius Recent Developments/Updates

Table 95. Eli Lilly Company Information

Table 96. Eli Lilly Description and Business Overview

Table 97. Eli Lilly Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 98. Eli Lilly Broluzumab Biosimilars Product

Table 99. Eli Lilly Recent Developments/Updates

Table 100. Bayer Company Information

Table 101. Bayer Description and Business Overview

Table 102. Bayer Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 103. Bayer Broluzumab Biosimilars Product

Table 104. Bayer Recent Developments/Updates

Table 105. Amgen Company Information

Table 106. Amgen Description and Business Overview

Table 107. Amgen Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 108. Amgen Broluzumab Biosimilars Product

Table 109. Amgen Recent Developments/Updates

Table 110. PlantForm Company Information

Table 111. PlantForm Description and Business Overview

Table 112. PlantForm Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 113. PlantForm Broluzumab Biosimilars Product

Table 114. PlantForm Recent Developments/Updates

Table 115. PharmaPraxis Company Information

Table 116. PharmaPraxis Description and Business Overview

Table 117. PharmaPraxis Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 118. PharmaPraxis Broluzumab Biosimilars Product

Table 119. PharmaPraxis Recent Developments/Updates

Table 120. Samsung Bioepis Company Information

Table 121. Samsung Bioepis Description and Business Overview

Table 122. Samsung Bioepis Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 123. Samsung Bioepis Broluzumab Biosimilars Product

Table 124. Samsung Bioepis Recent Developments/Updates

Table 125. Centus Company Information

Table 126. Centus Description and Business Overview

Table 127. Centus Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 128. Centus Broluzumab Biosimilars Product

Table 129. Centus Recent Developments/Updates

Table 130. Cadila Pharmaceuticals Company Information

Table 131. Cadila Pharmaceuticals Description and Business Overview

Table 132. Cadila Pharmaceuticals Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 133. Cadila Pharmaceuticals Broluzumab Biosimilars Product

Table 134. Cadila Pharmaceuticals Recent Developments/Updates

Table 135. Dr Reddy's Company Information

Table 136. Dr Reddy's Description and Business Overview

Table 137. Dr Reddy's Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 138. Dr Reddy's Broluzumab Biosimilars Product

Table 139. Dr Reddy's Recent Developments/Updates

Table 140. Aurobindo Pharma Company Information

Table 141. Aurobindo Pharma Description and Business Overview

Table 142. Aurobindo Pharma Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 143. Aurobindo Pharma Broluzumab Biosimilars Product

Table 144. Aurobindo Pharma Recent Developments/Updates

Table 145. Biocad Company Information

Table 146. Biocad Description and Business Overview

Table 147. Biocad Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 148. Biocad Broluzumab Biosimilars Product

Table 149. Biocad Recent Developments/Updates

Table 150. MAbxience Company Information

Table 151. MAbxience Description and Business Overview

Table 152. MAbxience Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 153. MAbxience Broluzumab Biosimilars Product

Table 154. MAbxience Recent Developments/Updates

Table 155. Hetero Company Information

Table 156. Hetero Description and Business Overview

Table 157. Hetero Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 158. Hetero Broluzumab Biosimilars Product

Table 159. Hetero Recent Developments/Updates

Table 160. Biocon Company Information

Table 161. Biocon Description and Business Overview

Table 162. Biocon Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 163. Biocon Broluzumab Biosimilars Product

Table 164. Biocon Recent Developments/Updates

Table 165. Kirin Biologics Company Information

Table 166. Kirin Biologics Description and Business Overview

Table 167. Kirin Biologics Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 168. Kirin Biologics Broluzumab Biosimilars Product

Table 169. Kirin Biologics Recent Developments/Updates

Table 170. Mylan Company Information

Table 171. Mylan Description and Business Overview

Table 172. Mylan Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 173. Mylan Broluzumab Biosimilars Product

Table 174. Mylan Recent Developments/Updates

Table 175. BeiGene Company Information

Table 176. BeiGene Description and Business Overview

Table 177. BeiGene Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 178. BeiGene Broluzumab Biosimilars Product

Table 179. BeiGene Recent Developments/Updates

Table 180. Innovent Company Information

Table 181. Innovent Description and Business Overview

Table 182. Innovent Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 183. Innovent Broluzumab Biosimilars Product

Table 184. Innovent Recent Developments/Updates

Table 185. Qilu Pharmaceutical Company Information

Table 186. Qilu Pharmaceutical Description and Business Overview

Table 187. Qilu Pharmaceutical Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 188. Qilu Pharmaceutical Broluzumab Biosimilars Product

Table 189. Qilu Pharmaceutical Recent Developments/Updates

Table 190. Hengrui Pharmaceuticals Company Information

Table 191. Hengrui Pharmaceuticals Description and Business Overview

Table 192. Hengrui Pharmaceuticals Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 193. Hengrui Pharmaceuticals Broluzumab Biosimilars Product

Table 194. Hengrui Pharmaceuticals Recent Developments/Updates

Table 195. Hisun Pharmaceutical Company Information

Table 196. Hisun Pharmaceutical Description and Business Overview

Table 197. Hisun Pharmaceutical Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 198. Hisun Pharmaceutical Broluzumab Biosimilars Product

Table 199. Hisun Pharmaceutical Recent Developments/Updates

Table 200. TOT BIOPHARM Company Information

Table 201. TOT BIOPHARM Description and Business Overview

Table 202. TOT BIOPHARM Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 203. TOT BIOPHARM Broluzumab Biosimilars Product

Table 204. TOT BIOPHARM Recent Developments/Updates

Table 205. Luye Pharmaceutical Company Information

Table 206. Luye Pharmaceutical Description and Business Overview

Table 207. Luye Pharmaceutical Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 208. Luye Pharmaceutical Broluzumab Biosimilars Product

Table 209. Luye Pharmaceutical Recent Developments/Updates

Table 210. Henlius Company Information

Table 211. Henlius Description and Business Overview

Table 212. Henlius Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 213. Henlius Broluzumab Biosimilars Product

Table 214. Henlius Recent Developments/Updates

Table 215. Key Raw Materials Lists

Table 216. Raw Materials Key Suppliers Lists

Table 217. Broluzumab Biosimilars Distributors List

Table 218. Broluzumab Biosimilars Customers List

Table 219. Broluzumab Biosimilars Market Trends

Table 220. Broluzumab Biosimilars Market Drivers

Table 221. Broluzumab Biosimilars Market Challenges

Table 222. Broluzumab Biosimilars Market Restraints

Table 223. Research Programs/Design for This Report

Table 224. Key Data Information from Secondary Sources

Table 225. Key Data Information from Primary Sources

Table 226. Authors List of This Report

List of Figures

Figure 1. Product Picture of Broluzumab Biosimilars

Figure 2. Global Broluzumab Biosimilars Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Broluzumab Biosimilars Market Share by Type: 2024 & 2031

Figure 4. Beovu Product Picture

Figure 5. Vsiqq Product Picture

Figure 6. Others Product Picture

Figure 7. Global Broluzumab Biosimilars Market Value by Application (2020-2031) & (US$ Million)

Figure 8. Global Broluzumab Biosimilars Market Share by Application: 2024 & 2031

Figure 9. ARMD

Figure 10. Kaposi Sarcoma

Figure 11. Glioblastoma

Figure 12. Global Broluzumab Biosimilars Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Broluzumab Biosimilars Market Size (2020-2031) & (US$ Million)

Figure 14. Global Broluzumab Biosimilars Sales (2020-2031) & (Units)

Figure 15. Global Broluzumab Biosimilars Average Price (K USD/Unit) & (2020-2031)

Figure 16. Broluzumab Biosimilars Report Years Considered

Figure 17. Broluzumab Biosimilars Sales Share by Manufacturers in 2024

Figure 18. Global Broluzumab Biosimilars Revenue Share by Manufacturers in 2024

Figure 19. Global 5 and 10 Largest Broluzumab Biosimilars Players: Market Share by Revenue in Broluzumab Biosimilars in 2024

Figure 20. Broluzumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 21. Global Broluzumab Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 22. North America Broluzumab Biosimilars Sales Market Share by Country (2020-2031)

Figure 23. North America Broluzumab Biosimilars Revenue Market Share by Country (2020-2031)

Figure 24. U.S. Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Canada Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Europe Broluzumab Biosimilars Sales Market Share by Country (2020-2031)

Figure 27. Europe Broluzumab Biosimilars Revenue Market Share by Country (2020-2031)

Figure 28. Germany Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. France Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. U.K. Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Italy Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Russia Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Asia Pacific Broluzumab Biosimilars Sales Market Share by Region (2020-2031)

Figure 34. Asia Pacific Broluzumab Biosimilars Revenue Market Share by Region (2020-2031)

Figure 35. China Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Japan Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. South Korea Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. India Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Australia Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Taiwan Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Indonesia Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Thailand Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Malaysia Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Philippines Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Latin America Broluzumab Biosimilars Sales Market Share by Country (2020-2031)

Figure 46. Latin America Broluzumab Biosimilars Revenue Market Share by Country (2020-2031)

Figure 47. Mexico Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Brazil Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Argentina Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Middle East and Africa Broluzumab Biosimilars Sales Market Share by Country (2020-2031)

Figure 51. Middle East and Africa Broluzumab Biosimilars Revenue Market Share by Country (2020-2031)

Figure 52. Turkey Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Saudi Arabia Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. U.A.E Broluzumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Global Sales Market Share of Broluzumab Biosimilars by Type (2020-2031)

Figure 56. Global Revenue Market Share of Broluzumab Biosimilars by Type (2020-2031)

Figure 57. Global Broluzumab Biosimilars Price (K USD/Unit) by Type (2020-2031)

Figure 58. Global Sales Market Share of Broluzumab Biosimilars by Application (2020-2031)

Figure 59. Global Revenue Market Share of Broluzumab Biosimilars by Application (2020-2031)

Figure 60. Global Broluzumab Biosimilars Price (K USD/Unit) by Application (2020-2031)

Figure 61. Broluzumab Biosimilars Value Chain

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Broluzumab Biosimilars market? zhanKai

The top companies in the global Broluzumab Biosimilars market are Novartis、Genentech、Roche.

Related Reports

Broluzumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Broluzumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 189
USD 3950.00
(Single User License)
Global Broluzumab Biosimilars Market Research Report 2024
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Published Date: 2024-01-20
Pages: 109
USD 2900.00
(Single User License)
Broluzumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Published Date: 2024-01-11
Pages: 164
USD 3950.00
(Single User License)

Broluzumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Broluzumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 189
USD 3950.00 (Single User License)
Global Broluzumab Biosimilars Market Research Report 2024
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Published: 2024-01-20
Pages: 109
USD 2900.00 (Single User License)
Broluzumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Published: 2024-01-11
Pages: 164
USD 3950.00 (Single User License)